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Abstract. 
 
 Praziquantel (PZQ) is efficacious against Schistosoma  mansoni. This was prospective cohort study. This study 
was carried out at Kigungu fishing village, Entebbe, Uganda. The goal of the study was to establish cost effective regiment 
for mass drug administration (MDA) of Praziquentel in the morbidity reduction of S.mansoni infection. In January 2004, nine 
hundred and forty five (945) participants were registered in this study. Our analysis was based on examining microscopically 
three slides prepared from each of 945 stool specimens delivered by each of the participant using modified Kato/Katz 
method. These included male and female, children and adults living in Kigungu fishing village in Entebbe Uganda. In total 
901, cohorts were re-examined for infections clearance six months later in July 2004 and 18 months later in June 2005, 625 
cohorts were again re-evaluated for S.mansoni infections after the baseline study. At baseline, (448) of 945 (47.5%) cohorts 
were S. mansoni positive. All these participants were treatment with a single oral dose of praziquantel at 40mg/kg. At the 
same time, 495 (52.5%) were S. mansoni negative. Of the 625 (66.3%) cohorts who came back for final review, 80 (12.8%) 
were still positive for S. mansoni while 210 (33.6%) remained negative after the base line treatment with praziquantel. On the 
other hand 103 (16.3%) of cohorts who were initially negative at the base line became S.mansoni positive after 18 months 
and 213(34.1%) remained negative for S.mansoni. The force of re-infection after six months was significant {(P=0.0001), 
(OR 0.47) CI at 95% (0.31-0.71)}. Nevertheless the force of reinfection was not significant after 18 months {(P=0.766), (OR 
0.95) CI at 95% (0.68-1.34)}.The geometric mean eggs excretion of the 80 cohorts who were S.mansoni positive at 18 
months was 151.967.This did not reach the geometric mean egg excreted by the same cohorts at baseline which was 285.05. 
The egg excretion was reduced by 46.8%. Similarly there was marked decrease in clinical symptoms amongst the cohorts. 
Our study suggests evidence of long-term benefit of praziquantel in Kigungu and that a yearly administration of praziquantel 
to the community could be a regiment for mass drug administration (MAD) for this community to control schistosomiasis 
morbidity.  
 
 
Introduction 
 
Praziquantel (PZQ) is efficacious against Schistosoma mansoni (Sleigh et al., 1985). Presently in Uganda, one of 
schistosomiasis endemic countries in sub Saharan Africa, PZQ is the drug of choice in controlling morbidity due to 
schistosomiasis because the mean cost of treatment per dose per person in Uganda is about $0.3 (Mott, 1982; Doenhoff et al., 
2002). In spite of its relative low cost, Uganda Ministry of Health budget is still unable to procure adequate PZQ for short 
period mass chemotherapy. Previous studies in the seventies showed that in Uganda, the efficacy of PZQ was evaluated after 
six months to determine the cure proportion (Odongo-Aginya and Mugisha, 1987). Nevertheless in other tropical countries, 
few studies evaluated the efficacy of PZQ at the interval of one year (Stelma et al., 1995; Correa-Oliveira, et al., 2000; Davis, 
1993).  At present, studies in different endemic settings using the single oral dose regiment of 40 (mg/kg wt) of PZQ against 
S. mansoni, and mixed infections, the efficacy of PZQ stands at 60-90 % (Cioli and Pica- Mattoccia, 2000). Extensive use of 
PZQ in Uganda and elsewhere in the tropics has been linked to the development of parasite resistance to the drug. This is 
evidenced by reduced cure proportion in humans treated with PZQ in the Richard Toll area of Senegal (Stelma et al., 1995). 
However, factors like intensity of infections and high transmission of infections have been known to influence 
schistosomicidal activity of PZQ (Gryseels, 1994). In spite this fact, repeated treatment with PZQ has been shown to improve 
cure proportion as observed in West Nile districts of Uganda areas of high transmission and intensity (Ongom and Bradley, 
1972). 
  Consequently it was deemed necessary to establish a treatment regimen for schistosomiasis endemic foci of 
Uganda. This study investigated specifically the effect of PZQ on cure proportion as measured by S. mansoni egg reduction 
in the cohorts 18 months after treatment in Kigungu-fishing village, a community with high exposure risk to S. mansoni 
infection in order to establish morbidity reduction, hence, the patients benefit from treatment with PZQ and cost effective 
treatment regimen that could be adopted in Uganda. 
Odongo-Aginya et al.,  Afr. J. Infect. Dis. (2011) 5(2): 33 - 39 
 
34
Patients and Methods    
Study sample 
 
The participants were registered in the three studies using their study code numbers, names, sex, age, home 
locations and the names of head of the families. Nine hundred and forty five residents of Kigungu fishing village were 
registered in this study in January 2004. Their stool specimens were examined microscopically for S.mansoni eggs. Out of 
the 945 participants examined 448 (47.4%) of them were stool positive for S. mansoni, and 495 (52.6%) participants were 
stool negative for S. mansoni. Treatment with PZQ at 40mg/kg was administered to the 448 S. mansoni positive participants. 
While the S.mansoni stools negative participants were treated for other ailments where necessary. The two categories of 
participants were requested to report for review in July 2004. Six months later, 901 out of 945 (95.5%) cohorts were 
reviewed. These consisted of 433 out of 448 (96.7 %) treated S. mansoni positive cohorts. On re-examination of their stool 
specimens, 40 cohorts still had S.mansoni egg. They were again treated but were left out of the study. Similarly 468 out 495 
(94.5%) who were S.mansoni negative at baseline were reviewed. Ninety two of them were found with eggs of S. mansoni in 
their stool. They were treated with PZQ 40mg/kg body weight and left out of the study.  Twelve months later 625 out of 769 
(81.3%) of the cohorts came back for the third evaluation. Among the 310 cohorts who were stool negative after PZQ 
clearance at baseline 80 became positive for S. mansoni while 230 were still stool negative for S. mansoni. Meanwhile among 
the 315 cohorts who were S.mansoni negative at baseline, 102 Patients became infected with S. mansoni while 213 cohorts 
continued to be stool negative for S. mansoni (see flow chart below).  
 
Study area 
 
This study was conducted in Kigungu fishing village, situated along Lake Victoria in Entebbe peninsula. This 
village is located to the extreme end of the peninsula, at latitude 350 to 380 East and 030 to 070 North. Kigungu is about 15 
kilometers from Entebbe Town Municipality and about half a kilometer from the Entebbe international airport. This fishing 
village was selected because previously studies on S. mansoni and other soil-transmitted helminths showed that the village is 
a focus for these parasites (Odongo-Aginya and Mugisha, 1987). The population of Kigungu is estimated to be 6,000 people 
with nearly an equal sex 1:1 ratio. They are mainly fishermen and women. Besides fishing, they do a little subsistence 
farming mostly for food crops.  Their water exposure is high, hence, the source of infection and reinfection.  
 
Procedure of the study.  
 
                  Informed consent was obtained from all the participants. One thousand Residents who had consented to 
participate in the study and children between 5 and 18 years old who had been granted permission to participate in the study 
by their parents/guardians and have not taken antischistosomal treatment six months prior to the baseline study were 
recruited. This explains the reason for the 55 people who were excluded from the base line registration. Those giving their 
consent and were literate, were asked to sign an official form showing acceptance. Meanwhile the illiterate patients used 
thumb prints on official form showing acceptance. Patients unwilling to participate in the study were not penalised in any 
way and normal clinical services and treatments including antischistosomal therapy were not conditioned to the patient’s 
participation in this research.  
  Residents reported for the study at our outreach clinic in Kigungu primary school between 9 a.m and 12 p.m every 
project workday. On each working day, thirty consecutive patients in a row, and who met the inclusion criteria, were 
registered into the study. This was to allow the laboratory technologist to examine the specimens in the afternoon and deliver 
the stool results the following day in the morning for treatment. The patients to be recruited were interviewed and examined 
by a physician and a nurse during initial screening. The physicians examined the patients clinically with special attention to 
condition of the abdominal organs commonly affected by S. mansoni worm. Anaemia and fever were also clinically noted.  
Patients with body temperature greater than 37.50C had blood smear test for malaria parasites done.  
                 All patients infected with S. mansoni were treated at the study site with praziquantel (from Medochemie 
Ltd.Limassol-Cyprus Europe) at 40 mg per kg body weight. Illnesses, other than schistosomiasis, detected during 
examination were appropriately treated or referred to other health facilities. Patient’s privacy was duly respected.  
 
Determination of intensity of intestinal worms 
 
A stool container labelled with individual identification was given to each patient to return with about 5-10 gram of 
stool specimen. Eggs in the stool were quantified using modified Kato-Katz method (Odongo-Aginya, et al., 1997; Mahdi, et 
al., 1999). Essentially each stool specimen was initially strained through a stainless steel sieve 250m mesh size to remove 
artefacts. The strained stool was then used to fill a hole in a template measuring 41.7 milligram of stool. Three separate 
aliquots of such measured weights were delivered on three separate slides from each stool specimen. About 10l drop of 
compound stain consisting of eosin 5% in 10% formalin and nigrosin 7.5% in 10% formalin was added to stool smear on 
each slide. The stain was stirred in the stool smear on the slide. A wettable cellophane cover slip cut 32 x 41 mm pre soaked 
in 50% glycerine was placed on the stained stool smear and pressed down. The excess stain from the smear on slide was 
blotted out on an absorbent paper before the prepared slide was read immediately using objective x 10. The arithmetic mean 
of the eggs counted in three slides was recorded as the count in 41.7 milligram of stool. To convert the mean egg count into 
egg per gram of faeces a factor of 24 was multiplied by the mean of the eggs counted i.e. number of eggs (n) x 1000 mg/ 41.7 
mg = 24 x n = eggs per gram faeces. Intensities of infections were classified as follows: low 1-100 eggs per gram, medium 
101-400 and high ≥ 401eggs per gram of stool (Sleigh et al., 1985).  
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Figure 1: Flow chart showing the follow up of patients from first recruitment up to 18 months 
 
 
Data management and statistical analysis  
 
                Data were double entered using Microsoft Excel and crosschecked by different individuals.  The arithmetic mean 
egg counts of the individuals were categorised according to infection intensities as follows 0-100; 101-200; 201-300; 301-
400; and ≥ 401. Similarly age group was also categorised into five groups 5-10; 11-20; 21-30; 31-40 and ≥ 41. The cure 
proportion was calculated from individuals who had no S. mansoni egg in their stool after treatment divided by the total 
number of individuals who had S. mansoni egg in their stool before treatment multiply by 100%. The percentage of egg count 
reduction was calculated as the geometric mean egg count after treatment/ by geometric mean egg count before treatment 
multiplied by 100%.  The T-test was used to compare the intensity of infections between S. mansoni amongst 80 patients who 
were reinfected 18 months later and 102 patients who were S. mansoni negative but became S. mansoni positive 18 months 
later at 95% level of confidence while the Chi X 2  was used to show the force of infection which was evaluated by egg count 
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reduction and the cure proportion after 6 months and 18 months against force of reinfection in six months and 18 months 
after treatment at 95% level of confidence.  
 
 
 
Results 
 
A very small proportion (2.4%) of the 433 patients who were S. mansoni positive at the baseline survey continued 
to excrete eggs of S. mansoni in their faeces. Meanwhile among the 468 negative patients at the baseline (2.5%) of them were 
infected (Figure 1). Comparison of eggs intensity excreted by the 80 cohorts who were positive at base line, cleared their 
infections after six months but got re-infected twelve months later are shone in (Table 1).Meanwhile    Comparison of 
Intensity of S. mansoni amongst 80 patients who were reinfected 18 months later and 102 patients who were S. mansoni 
negative but became S. mansoni positive 18 months later by Student’s T-test did not find any significant difference This 
implies that the benefit of treatment with PZQ continues to be felt in the community even after 18 months (Table 2).  
 
 
 
Table 1: Comparison of Intensity of S. mansoni amongst 80 cohorts who were reinfected 18 months but had cleared the 
infections after six months. 
 
BASE LINE INFECTION OF THE 80 COHORTS INFECTION AFTER 18 MONTHS  OF 
SAME 80 COHORTS 
Age 
group 
No of cohorts / % of infected 
before and after  18 months in 
age groups 
Eggs excreted at base 
line 
Geometric 
Mean count 
Eggs excreted after 18 
months 
Geometric 
Mean count 
5-10 9 (11.25) 2632 463.86 2139 133.77 
11-20 47 (58.75) 18812 285.05 9680 151.97 
21-30 13 (16.25) 9184 317.11 2662 151.74 
31-40 7 (8.75) 2200 284.20 1924 156.43 
 41 4 (5.0) 1079 260.08 396 138.94 
TOTAL 80 (100) 33897 285.05 16801 151.96 
 
NB The Table 1: showed that there was 50.4 percent reduction in eggs excretion from the 80 cohorts studied at base line and 
18 months later.   
 
 
Table 2: Comparison of Intensity of S. mansoni amongst 80 patients who were reinfected 18 months later and 102 patients 
who were S. mansoni negative but  became S. mansoni positive 18 months later.  
Re-infection with  S. mansoni 18 months later N=80 Infection with S. mansoni 18months amongst 102 patients who were 
initially S.mansoni negative 
Age group N Mean eggs Std  N Mean eggs Std T test (p-value) 
5-10 9 133.77 202.8 23 79.4 119.9 0.555 
11-20 47 151.97 173.2 47 60.9 85.6 0.031* 
21-30 13 151.74 232.4 17 206.6 244.2 0.265 
31-40 7 156.43 48.7 9 131 251.3 0.286 
 41 4 138.94 28.9 6 20 6.9 0.427 
TOTAL 80 151.96 152.09 102 105.03 179.86 0.586 
 
Legend:  Std = standard deviation.  N= 80 the total number individuals re- infected with S. mansoni after the second 
treatment and the 102 individuals who were negative initially but became infected at the end of the 18 months. * The only 
age group which showed significant T test. ∑=Sum of mean 
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Comparing the difference between those who remained negative after treatment with those who were infected in the baseline 
study  the force of clearance of PZQ  showed significant difference  (P= 0.001). Similarly the force of clearing the infection 
of PZQ after 18 was also significant (P=0.001).   While the re-infection rate was significant (P=0.001) after six months there 
was no significant difference in the re-infection rate after 18 months (P= 0.766) (Table 2). 
 
 
Discussion 
 
Several studies of infections and reinfection with Schistosoma mansoni after treatments with PZQ of residents 
living in endemic areas in the Tropics have been shown to lead to reduction of prevalence and intensity to re-infection after 
treatment. The re-infection prevalence and intensity have been shown never to equal before treatment level (Correa-Oliveira, 
et al., 2000). This study showed that there was reduction in the percentage of infection from {47.4% (448 out of 945) to 
25.8% (80 out 310)} and the percentage reduction of the sum of eggs excretion was 50.4% in post PZQ therapy. This was 18 
months after the initial treatment with PZQ 40mg/kg/wt. (Stelma et al., 1995; van.Liehout, et al., 1999). 
 
Table 3: Cure rates and reinfection rates 
Cure rates after 6 months  P value OR (CI) 
393/433 92/468 0.001   4.63 (3.53 – 6.06) 
Cure rates after 18 months    
210/310 102/376 0.001 2.20 (1.87 – 3.34) 
Re infection rate after 6 months    
40/432 92/469 0.001 0.47 (0.31 – 0.71) 
Re infection rate after 18 months    
80/310 102/376 0.766 0.95 (0.68 – 1.34) 
 
Legend: cure rate after 6 months and 18 months against force of re-infection in six months and 18 months after treatment 
In addition, the reductions of the clinical symptoms observed before and after treatment further demonstrate the evidence of 
long benefit of parazequantel in this community.  In S. mansoni positive patients most patients had one or more clinical 
symptoms before treatment, (data not shown). Nevertheless after treatment, most of the asymptomatic and some with 
abdominal pains, diarrhoea and blood in stool became S. mansoni negative. These indicated that those persisting symptom 
could be of different causes other than those for S. mansoni. We detected mixed infection of S.mansoni with others intestinal 
parasites including soil transmitted helminths and protozoan infections. There were reductions of major clinical symptoms 
while the minor symptoms disappeared after treatment (Table 3).  
 
 
Table 4:  Percentage of common clinical symptoms observed among the study participants. 
Clinical 
symptoms %  
Abdominal 
pain 
Diarrhoea Blood in 
stool   
Blood in 
urine  
Ascites  Blood 
vomiting  
Asymptomatic 
Before 
treatment 
44.5(421*) 21.1(199*) 13.3(126*) 0.8(8*) 0.4(4*) 0.6(6*) 13.8 (130*) 
After treatment 30.1(188*) 18.2(134*) 6.6(41*) 0 0 0 37(231) 
 
Legend: Clinical symptoms observed* before and after treatment. Before treatment, S. mansoni positive patients had one or 
more of these clinical symptoms (not shown). Nevertheless after treatment most of the asymptomatic and some symptomatic 
patients became S. mansoni negative. There were reductions of major clinical symptoms while the minor symptoms 
disappeared after treatment. The percentage clinical symptoms was the ratio of observed symptoms to total number of the 
patients before or after treatment {(N/945*100); (N/625*100)}.  
 
 
We deliberately set a period of 18 months in total with the first six months for the assessment of the success of 
baseline treatment. We subsequently followed the cohorts up for twelve months to allow the study residents exposures to 
reinfection. This was to find out the level of resistance and susceptibility developed after treatment (Mott, 1982).  Follow up 
studies to establish the force of reinfection after treatment with PZQ after short interval has been documented (Mott, 1982; 
Davis, 1993). Nevertheless this short term administration of treatment is uneconomical for most countries in the Tropic. 
Therefore, this study was to establish a treatment regiment for economical reasons for Kigungu and eventually elsewhere. 
Most schistosomiasis control Programmes in the Tropics are based on a six monthly single dose administration of PZQ to 
large communities. Repeated treatment to re-infected individuals is recommended depending on the degree of transmission in 
areas (Cioli, 2000). In spite of the low cost of PZQ, most counties in Africa are unable to procure adequate PZQ for mass 
chemotherapy. Study of this kind helps to establish treatment regiments for communities in schistosomiasis endemic areas in 
the tropical countries with meagre budget for helminth control programmes (Sleigh et al., 1985; Mott, 1982).  
Mutapi in their study of changes in specific anti-egg antibody levels with PZQ followed their patients after 9 
months (Mutapi, et al., 1998). In addition, Correa-Oliveira in their natural versus drug induced resistance in S. mansoni 
infections study followed their patients for five years at an interval of one year (Correa-Oliveira, et al., 2000). Our study 
demonstrating long term benefits of PZQ covered a period of 18 months. It is of importance to note here that Immunological 
responses due to dead S.mansoni adult worms and eggs antigens could be contributing to the resistance to the reinfections 
(Ana, et al.1995; Khalife, et al., 1986; Dunne, et al., 1992). Repeated treatment with PZQ within short intervals was also 
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found to have no effect on the re-infection period in children in their first decade of life (Correa-Oliveira, et al., 2000). 
Nevertheless, the cure proportion of PZQ is greater if the treatment is repeated within a short period but the cost of the 
treatment remains relatively high (Correa-Oliveira, et al., 2000; Ongom and Bradley 1972).  
On the other hand lower cure proportion of 18-39% was observed in very intense focus of S. mansoni infection in 
northern Senegal (Stelma et al., 1995; van.Leihout, et al., 1999).  In our study, infections were lower for higher age groups ≥ 
21 years indicating that there is relationship between S. mansoni infection and age (Tables 1and 2). This is in line with 
phenomena commonly observed in endemic areas (Gryseels, 1994). Pre-treatment infections categorised according to the 
levels of intensity  showed that 197 patients in Kigungu were in low intensity levels (1-100 epg), 145 of them were in the 
middle levels of intensity (101-400epg) and only 106 of them excreted high egg count greater than 401 epg (Sleigh et al., 
1985). We observed that 213 cohorts remained S. mansoni negative through out the study. They confirmed to us that they 
have never been treated at any time for S. mansoni. The observation that 213 patients remained uninfected in all studies 
points out to an interesting situation in which some of the residents live all their lives in S. mansoni endemic areas but do not 
get the infection. This group of patients commonly known as endemic normal (putative resistance) was always stool negative 
for S. mansoni eggs. The putative resistant people of Kigungu have been found to be stool negative for S. mansoni before and 
after treatment (Gazzinelli, et al., 1985). 
Intensities of infection influence manifestation of clinical schistosomiasis (N’ Goran, 2003). From our records 
before treatment, majority of patients with multiple clinical symptoms such as abdominal pains, diarrhoea and blood in stool 
were positive for S. mansoni (Table 4). There were a few male patients with haematuria in this study but they were all 
negative for S. haematobium. Many studies showed that S. mansoni is the predominant species of schistosome in Uganda 
(Ongom and Bradley 1972; Odongo-Aginya and Mugisha, 1987). However, Schwertz 1951 and Cridland 1957 reported 
visceral schistosomiasis in Lango and Acholi (Schwert, 1951; Cridland, 1957). The few patients with ascites detected in this 
study were all positive for S. mansoni.  Ascites is an indicator of chronic schistosomiasis with enlarged liver and spleen 
palpable (Davis, 1993; Ongom and Bradley 1972).  Histories of blood vomiting were also recorded but they were not severe 
oesophageal varices bleeding linked to S. mansoni. The latter two clinical symptoms are characteristic of chronic 
schistosomiasis (Mott, 1982; Correa-Oliveira, et al., 2000). Age and pre-treatment intensity were the main host- parasite 
factors, which were significantly associated with S. mansoni low cure proportion in this study. This study also adds evidence 
of association between PZQ cure proportion, age and pre-treatment intensity. This observation stresses the need of two doses 
of PZQ within a standardised period to reduced morbidity due to heavy schistosome infections and avoids environmental 
contamination with S.mansoni eggs in endemic areas (N, Goran, 2003)   
Our stool analysis was based on a single stool specimen from each patient. Nevertheless, three stool smears were 
prepared from each specimen to increase the accuracy of the egg count in each stool specimen (Ongom and Bradley 1972; 
Odongo-Aginya, et al., 1997). In most community-based studies, cure proportion have been estimated based on only one or 
two slides Kato/Katz reading usually derived from a single stool sample (Kathrine, et al., 1999). The multiple stool samples 
procedure is particularly relevant when the overall geometric mean egg count is low, because it increases the chances of 
estimating true cure proportion (Sleigh et al., 1985, Mott, 1982).  
Our findings raise very high hope about the long term benefit of morbidity reduction initiated by praziquantel 
treatment. Nevertheless, since praziquantel is used widely in Africa especially in Uganda for large-scale treatment of 
schistosomiasis, it is relevant to monitor praziquantel effectiveness and the development of the parasites resistance to the 
drugs according to the set time frame of a particular endemic focus (Mott, 1982; Stelma et al., 1995; Correa-Oliveira, et al., 
2000).  
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